Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma

Antonio Salar; Eva Domingo-Domenech; Carlos Panizo; Concepción Nicolás; Joan Bargay; Ana Muntañola; Miguel Canales; José Luis Bello; Juan Manuel Sancho; José Francisco Tomás; María José Rodríguez; Javier Peñalver; Carlos Grande; José Javier Sánchez-Blanco; Luis Palomera; Reyes Arranz; Eulogio Conde; Mar García; Juan Fernando García; Dolores Caballero; Carlos Montalbán

doi:10.1182/blood-2017-07-795302

Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma

Blood. 2017 Oct 12;130(15):1772-1774. doi: 10.1182/blood-2017-07-795302. Epub 2017 Aug 11.

Authors

Antonio Salar¹, Eva Domingo-Domenech², Carlos Panizo³, Concepción Nicolás⁴, Joan Bargay⁵, Ana Muntañola⁶, Miguel Canales⁷, José Luis Bello⁸, Juan Manuel Sancho⁹, José Francisco Tomás¹⁰, María José Rodríguez¹¹, Javier Peñalver¹², Carlos Grande¹³, José Javier Sánchez-Blanco¹⁴, Luis Palomera¹⁵, Reyes Arranz¹⁶, Eulogio Conde¹⁷, Mar García¹⁸, Juan Fernando García¹⁹, Dolores Caballero²⁰, Carlos Montalbán¹⁰

Affiliations

¹ Department of Hematology, Hospital del Mar, Barcelona, Spain.
² Department of Hematology, Hospital Durans i Reynals, Barcelona, Spain.
³ Department of Hematology, Clínica Universitaria de Navarra, Pamplona, Spain.
⁴ Department of Hematology, Hospital Central de Asturias, Asturias, Spain.
⁵ Department of Hematology, Hospital Son Llatzer, Mallorca, Spain.
⁶ Department of Hematology, Hospital Universitario Mutua de Terrassa, Terrassa, Spain.
⁷ Department of Hematology, Hospital Universitario La Paz, Madrid, Spain.
⁸ Department of Hematology, Complejo Universitario de Santiago, Santiago de Compostela, Spain.
⁹ Department of Hematology, Hospital Germans Trias i Pujol, Badalona, Spain.
¹⁰ Department of Hematology, MD Anderson Cancer Center, Madrid, Spain.
¹¹ Department of Hematology, Hospital Universitario de Canarias, Tenerife, Spain.
¹² Department of Hematology, Hospital Fundación Alcorcón, Alcorcón, Spain.
¹³ Department of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain.
¹⁴ Department of Hematology, Hospital Morales Meseguer, Murcia, Spain.
¹⁵ Department of Hematology, Hospital Clínico Lozano Blesa, Zaragoza, Spain.
¹⁶ Department of Hematology, Hospital Universitario La Princesa, Madrid, Spain.
¹⁷ Department of Hematology, Hospital Marqués de Valdecilla, Santander, Spain.
¹⁸ Department of Anatomic Pathology, Hospital Universitario Miguel Servet, Zaragoza, Spain.
¹⁹ Department of Anatomic Pathology, MD Anderson Cancer Center, Madrid, Spain; and.
²⁰ Department of Hematology, Hospital Clínico de Salamanca, Salamanca, Spain.

PMID: 28801448
DOI: 10.1182/blood-2017-07-795302

No abstract available

Publication types

Clinical Trial, Phase II
Letter
Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Aged, 80 and over
Bendamustine Hydrochloride / therapeutic use*
Female
Humans
Longitudinal Studies
Lymphoma, B-Cell, Marginal Zone / drug therapy*
Lymphoma, B-Cell, Marginal Zone / mortality
Male
Middle Aged
Prognosis
Recurrence
Remission Induction
Rituximab / therapeutic use*
Survival Analysis

Substances

Rituximab
Bendamustine Hydrochloride